Resistant Depression Treatment Market to Reach Over US $ 1 Billion by 2026 End

  • 30 Apr 2019

The global resistant depression treatment market is foreseen to value over US$ 1 billion by the endof 2026and register at a CAGR of 3%during the forecast period of 2019-2026.

The astounding disclosure of  World Health Organisation (WHO) in regards to persistent depressive disorder among young population is indicative of a global need for innovative depression treatment. Innovative because contemporary anxiety and depression treatment medicines remain sterile amongst large patient base as they do not respond or scarcely respond to such medications. With ketamine-based depression treatment being backed up by the Food and Drug Administration (FDA), tremendous innovative opportunities flood the resistant depression treatment market.

Resistant Depression Treatment Market Futuristic Opportunities Insight
Various market players are striving to harness the benefits of ketamine-based alternative depression treatment. They are focused on launching ground-breaking biopharmaceutical products that can be administered in hospital settings through the medicinal infusion. Besides, researchers at the National Institute of Mental Health, United States continue to verify new compounds like scopolamine in conjunction with non- pharmacological cures like magnetic brain stimulation therapies. Market players with devices that support such non-pharmacological treatments along with useful antidepressant drugs are projected to hold the keys to market dominance in the near future.

Global Resistant Depression Treatment Market, by Drug Type
•    Selective serotonin reuptake inhibitors
•    Serotonin-norepinephrine reuptake inhibitors
•    Tricyclic antidepressants
•    Monoamine oxidase inhibitors
•    Atypical agents

Selective serotonin reuptake inhibitors remain the first line of treatment, as these drugs are capable of blocking the reabsorption of serotonin in brain cells. This segment holds major revenue share. However, due to higher remission rates, alternate drug class like Serotonin-norepinephrine reuptake inhibitors are gaining higher adoption. Serotonin-norepinephrine reuptake inhibitors segment is estimated to grow at a robust CAGR during the forecast period.

Global Resistant Depression Treatment Market, by Distribution Channel
•    Hospital Pharmacies
•    Retail Pharmacies
•    Mail Order Pharmacies

Global Resistant Depression Treatment Market, by Region
•    North America
•    Latin America
•    Europe
•    Asia Pacific
•    Rest of the World

When it comes to mental disorders across the world North American region is highly prone to depression among the female and ageing population. Whereas resistant depression treatment remains the most neglected public health issue in both European and American subcontinents. However, growing clinical trials and alternative treatment research in a quest to control the cost of hospitalized treatment-resistant depression patients in North America makes it a dominant market shareholder. With increasing sedentary lifestyle and stress conditions, emerging nations in the Asia Pacific are demonstrating high potential for resistant depression treatment market upsurge over the next few years.

Competitive Landscape:  
•    Tier 1 players- established companies in the market with a major    market share
•    Tier 2 players 
•    Emerging players which are growing rapidly 
•    New Entrants  

FutureWise Key Takeaways 
•    Growth prospects
•    SWOT analysis 
•    Key trends 
•    Key data-points affecting market growth 

Objectives of the Study: 

•    To provide with an exhaustive analysis on the global resistant depression treatment market on the basis of drug type, distribution channel, and region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies  


Get unlimited analyst support and customise this study further to your requirements, contact